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Abstract. Aim: Comparison of the therapeutic effect of
treatment of non-muscle invasive bladder carcinoma (NMIBC)
after intravesical Interleukin-2 (IL-2) instillations in the presence
and absence of a marker tumour. Materials and Methods: Two
pilot studies were performed in patients with NMIBC. The first
study (10 patients) was performed in Krakow (Poland), the
second (26 patients) in Vilnius (Lithuania). In Krakow the
tumours were treated with incomplete transurethral resection
(TUR) leaving a marker tumour of 0.5-1.0-cm followed by IL-2
instillations (3×106 IU IL-2) on five consecutive days. In Vilnius
the tumours were treated with complete TUR, followed by IL-2
instillations (9×106 IU IL-2) on five consecutive days. Results:
During 30 months follow-up, the recurrence-free survival was
5/10 (50%) and 6/26 (23%) after incomplete and complete TUR,
respectively. So, the ratio of the recurrence-free survival after
incomplete/complete TUR of 50/23=2.2. The median of the
recurrence-free survival is >20.5 months and 7 months after
incomplete and complete TUR, respectively. So, this ratio was
>20.5/7= >2.9. The hazard ratio which combines both the
chance of the disease recurrence and its timing for both censored
and uncensored cases was 0.53, again confirming the better
outcome after incomplete TUR. Conclusion: A possible
explanation for the better therapeutic effects after incomplete
TUR compared with complete TUR is that the marker tumour
has tumour-associated antigens (TAA) that could lead to an
immune reaction that is stimulated by local application of IL-2.
After complete TUR, no TAA are available to initiate and to
stimulate an immune reaction; consequently, local IL-2 therapy
is less effective after complete TUR. The results of these two pilot
studies have led to the recent start of a randomised prospective
clinical trial in which therapeutic effects of local IL-2 therapy
after complete and incomplete TUR are compared.
Non-muscle invasive bladder carcinoma (NMIBC) should be
treated with complete transurethral resection (TUR), in order to
obtain optimal staging and to reduce the chance of tumour
recurrence. However, recurrence rates at first follow-up
cystoscopy at three months varied between 7.4-45.8%, which is
a sign that the technique for TUR needs improvement (1). The
indication to start adjuvant chemo- or immunotherapy is based
on the results of the pathological and clinical findings, because
after evaluation of several randomized EORTC-GU-group trials,
patients can be classified into different risk group categories for
recurrence and progression, if there is no invasion into the
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muscle layer (2). Adjuvant chemo- and immunotherapy cause
side-effects, especially when given for a longer period, and there
are no prognostic factors identifying which patients need either
of the two treatments and, more importantly, there are no
predictive tools to identify those patients in whom disease will
progress in spite of or during adjuvant instillation. Improvements
in this field of genito-urinary cancer are, thus, still needed.
In order to avoid exposing many patients in a randomized
phase III trial to new intravesical agents, the EORTC-GU-
group developed the concept of the marker tumour (3-5):
during TUR, an untouched marker lesion of 0.5-1.0 cm is
deliberately left behind and two months after a course of
intravesical instillations, the effect of the investigational agent
on the marker tumour is evaluated by cystoscopy under
anaesthesia and resection of the tumour or place where the
marker lesion was located is carried out; the pathological report
has to indicate if there is still tumour or not. If the marker
tumour is not present anymore, then it is regarded to be due to
the therapeutic activity of the instilled investigational drug. If
the marker has not disappeared completely, then the instillation
therapy is regarded to be ineffective. The evaluation of
response to a marker tumour has been proven to be a safe
method to test new drugs (3-5). At the Fourth International
Bladder Consensus Conference, it was recommended that
marker tumour phase-II studies should be adopted as a standard
clinical trial practice for the evaluation of new agents to treat
NMIBC before embarking on large phase-III studies (3). 
Interleukin-2 (IL-2) has been used for cancer treatment with
local (intratumoural or peritumoural) application (6, 7).
Therapeutic effects were obtained in tumour models in mice
and rabbits (6, 8), and in veterinary (9, 10) and human (11, 12)
cancer patients. It was, thus, of interest to treat patients with
NMIBC with incomplete TUR, leaving a marker tumour,
followed by IL-2 instillation. Applying IL-2 instillation in
patients with NMIBC was interesting, because urinary IL-2
levels were increased in patients showing a positive response
to immunotherapeutic instillations (13-15).
In Krakow, patients were treated in a pilot study with
incomplete TUR followed by IL-2 instillations (11). To test the
reproducibility of the data, an identical trial was planned in
Vilnius (16, 17). However, the urologists in Vilnius regarded
application of the marker tumour concept to be unethical, as
they thought that this might harm the patients, due to tumour
progression. Hence, they performed complete TUR. This
enabled us to compare the effects of intravesical IL-2 therapy
in NMIBC in the presence and the absence of a marker tumour.
The therapeutic influence of incomplete and complete TUR
was expressed as: the ratio of the % of cases that did not
develop a recurrence during the follow-up period after
incomplete and complete TUR; the ratio of the median time
until tumour recurrence after incomplete and complete TUR;
the Kaplan Meier plot combining number and timing of
recurrences after incomplete and complete TUR.
If the ratio after incomplete/complete TUR is 1, then both
therapies exert an equal therapeutic effect; if the ratio is 2, then
the most effective therapy is twice as effective as the other
therapy. Etc.
The Krakow study 
Krakow: Materials, Methods and Results
In the first pilot study ten patients who had stage T1, grades 1
or 2 NMIBC were treated with incomplete TUR, leaving a
marker tumour. The patients gave their informed consent and
the Ethics Committee of the Jagellonian University Medical
College in Krakow, Poland, approved the protocol. Patients’
characteristics are shown in Table I. At TUR, a tumour of 0.5-
1.0 cm was left as a marker tumour. Cancer was histologically-
proven using the removed tumour tissue. Two days after TUR,
when the diagnosis was histologically-confirmed, 3×106 units
IL-2 in 50 ml saline plus 0.1% human serum albumin (HSA)
were instilled in the bladder through a catheter. The IL-2
solution remained in the bladder for two hours. IL-2 was
instilled on five consecutive days. The effect of IL-2 treatment
on the marker tumour was evaluated by cystoscopy and repeat
biopsy of the marker site two months after treatment. Any
marker tumour tissue present after two months was resected at
that time. Thereafter, during follow-up visits, tumour
recurrence was assessed with cystoscopy and biopsy. In case
of tumour recurrence, the patient was removed from the study.
The IL-2 was produced by Chiron/Novartis. Data of this study
have been published by Den Otter et al. in 1998 (11). The
results are summarized in Table II. Following treatment
complete response (CR; no tumour or tumour cells were
detectable anymore) was demonstrated in 5/10 (50%) patients
during the whole follow-up period of 30-54 months. The
median recurrence-free interval was > 20.5 months
(>30+11)/2). The findings for patients 1 and 2 in Tables I and
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Table I. Characteristics of patients in Krakow*.
Patient Age Gender Stage/ Number of Recurrence 
number (Years) grade preoperative rate/ 
tumours year
1 54 M pT1G1 3 3.3
2 34 M pT1G1 6 1.1
3 67 F pT1G1 2 2.5
4 62 F pT1G1-2 11 1.0
5 47 M pT1G1 3 1.2
6 43 F pT1G1 3 2.0
7 53 F pT1G1 2 6.0
8 71 M pT1G2 3 -
9 63 M pT1G1 2 -
10 69 M pT1G1 3 0.4
*Clinical study performed in Krakow (11). These patients received
incomplete TUR and IL-2 instillations.
II are interesting, since these patients had bladder carcinoma
for 7 and 11 years and were treated with 23 and 12 TURs; after
incomplete TUR and IL-2 instillations, both patients were
tumour-free during the whole follow-up period of 54 months.
The Vilnius study
Vilnius: Materials, Methods and Results 
In the second pilot study, 26 consecutive patients with stage Ta-
T1 G1, G2, or G3 NMIBC were treated with complete TUR and
intravesical IL-2 instillations. All patients gave their written
informed consent. This protocol was approved by the Lithuanian
Bioethics Committee and State Medicines Control Agency of
Lithuania (trial registration: EudraCT: 2004-002821- 30).
Patients’ characteristics are shown in Table III. Two days
postoperatively, following pathological confirmation of
NMIBC, 9X106 units IL-2 (Chiron/Novartis) in 50 ml saline
were instilled in the bladder through a catheter. The IL-2
solution remained in the bladder for two hours. IL-2 was
instilled on five consecutive days. The effect of the TUR plus
IL-2 therapy was evaluated during the regular follow-up visits
(cystoscopy and cytology) until tumour recurrence. If tumour
recurrence was demonstrated, the patient was removed from
this study. Preliminary data of this study have been published
by our group in 2010 and 2011 (16, 17).
The results of the Vilnius study are shown in Table IV. A total
of 2/26 of these patients (8 %) did not experience a recurrence
within the follow-up period of 86 months. The median
recurrence free interval of these 26 patients was 7 months.
Comparing both studies. The Kaplan-Meier curve of the
Proportion Recurrence-free Patients versus Months from TUR
(Figure 1), clearly shows that the therapeutic effects after
incomplete TUR are much better than after complete TUR.
Table V summarizes the statistical data comparing both studies.
The percentage of patients with recurrence-free survival during
the follow-up period after incomplete TUR was 2.2-times higher
(50% versus 23%). The median of the length of the recurrence-
free survival time after incomplete TUR was >2.9-fold that after
complete TUR (>20.5 versus 7 months). The hazard ratio
combining risk and event in censored and uncensored data, was
0.53 (95% confidence interval 0.23-1.19). Thus, all data
indicated much better therapeutic results with regard to
recurrences after incomplete TUR and complete TUR.
The patients characteristics differ between both studies.
Table VI compares the major differences between the patient
populations of both studies. The preoperative number of
tumours was a little bit lower in Krakow compared to Vilnius,
3.1 versus 3.5, respectively. The recurrence rate per year was
2.2 versus 1.5, respectively. The T-stage in the two trials differ:
all cases in the Krakow study and 8% in the Vilnius study were
T1. In Krakow 8/10 of the tumours were G1; in Vilnius 6/26
were G1 14/26 were G2 and 6/26 were G3. The patients in
Krakow were approximately 10 years younger, e.g. 56
compared to 66 years old in Vilnius. The percentage of males
was lower in Krakow, 60% compared to 80% in Vilnius. 
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Table II. Time (months) between treatment and recurrence after
incomplete TUR and local IL-2*.
Patient number Months between No recurrence during 
treatment whole follow-up 
and recurrence period (Months)
1 >54
2 >54
3 >30
4 2
5 2
6 11
7 >36
8 5
9 >30
10 2
*Clinical study performed in Krakow (11).
Table III. Patients’ characteristics in Vilnius*.
Patient Age Gender Stage/ Number of Recurrence
number (Years) grade preoperative rate/
tumours year
1 77 F pTaG2 >5 1.7
2 75 M pTaG2 >5 0.9
3 43 M pTaG2 4 2.1
4 53 M pTaG2 >5 0.3
5 56 M pTaG1 2 3.4
6 44 M pTaG2 >5 0
7 69 F pTaG1 1 0
8 78 M pTaG1 2 0.4
9 73 M pTaG2 >5 0.5
10 47 F pTaG2 1 0
11 73 M pTaG1 1 7.9
12 57 M pTaG2 >5 1.1
13 92 M pTaG2 >5 0
14 82 M pTaG2 3 5.7
15 57 M pTaG2 5 0
16 77 M pTaG2 >5 0
17 68 F pTaG2 >5 0.6
18 50 M pTaG1 1 3.7
19 49 M pTaG1 1 0
20 66 M pTaG2 >5 2.3
21 69 M pTaG3 2 0
22 66 M pTaG3 >5 0
23 76 M pTaG3 >5 0.3
24 61 M pTaG3 1 0
25 66 M pT1G3 >5 1
26 46 F pT1G3 1 6.1
*These patients received complete TUR and IL-2 instillations (data from
16, 17).
The underlying question is how do all these differences
influence the therapeutic outcome of both studies. Sylvester et
al. (2) have provided weight estimates for various factors on
the risk of recurrences after surgery for bladder carcinoma. The
measured parameter values (columns 2 and 3 of Table VI) are
weighed using the Sylvester weight estimates (column 4 and
5). Column 4 and 5 show the average weight of the parameter
values of column 2 and 3 on recurrence risk, calculated from
for each patient based on individual characteristics. Column 6
shows the predicted RFS after incomplete TUR based on the
comparison of data in column 4 and 5; also other data in the
literature are taken in account. A difference of more than 0.5
is considered better or worse, depending of its direction;
differences between 0.1 and 0.5 are considered ‘slightly’;
differences less than 0.1 are considered minimal. So, the result
is an educated guess of the influence of the differences in
parameter values in both trials on the RFS. The predicted effect
of T- and G-stage seem to balance each other between both
studies. Sex and marker tumour are not reported to have
significant effects. The small difference in preoperative tumours
and the difference in age have only small opposite effects. The
recurrence rate/year would indicate a worse prognosis for the
Polish study. Taken together, the influence of the first seven
parameters on the recurrence-free survival seems worse for the
Polish study compared to the Lithuanian study, the weights for
recurrence are 8.4 and 7.7, respectively. This means that after
incomplete TUR more recurrences can be expected ; weight
8.4. This cannot explain the obviously opposite effect we
found, as shown in Table V. 
Discussion 
IL-2 is thought to stimulate immune reactivity against tumour
associated antigens (TAA). In other words, TAA should initiate
an immune reaction, and IL-2 can stimulate this reaction. In
line with this view, a recent review showed that local
application of immunotherapeutics at the tumour site is much
more effective than systemic application (7). However, after a
well-performed TUR for NMIBC, no TAAs are left and
consequently IL-2 cannot stimulate the immune reaction
induced by TAA. This view is supported by the findings for
patients 1 and 2 in Krakow: these patients were treated for
recurrent bladder carcinoma with complete TUR for many
years, but finally they were ‘cured’ after treatment with the
antigenic marker tumour in combination with IL-2. The
presence or absence of TAA could explain the therapeutic
differences observed in these two pilot studies: taken together
these data suggest that the presence of a marker tumour leads
to improved therapeutic effects. 
There are some differences between these two studies that
have to be highlighted: Firstly, the difference in results may,
partly, be due to differences in the technique of the TUR
performed by individual surgeons (2). Secondly, the patients’
characteristics differed between both groups (Table VI). These
differences in patient characteristics seem to predict more
recurrences after incomplete TUR than after complete TUR.
However after therapy the opposite effect is obtained. 
Unfortunately, no pathology review was part of these pilot
studies. Thirdly, in Krakow IL-2 was dissolved in a solution of
saline with 0.1% HSA, whereas HSA was not used in Vilnius.
HSA was used in Krakow because IL-2 binds to HSA; this
prevents IL-2 sticking to the wall of syringes, catheters etc. In
Vilnius HSA was omitted; the IL-2 was dissolved in a
relatively small volume of saline; this prevents precipitation of
IL-2. Fourthly, in Krakow, 3×106 IU IL-2 were instilled daily,
whereas in Vilnius 9×106 IU were instilled daily. Urologists in
Vilnius preferred this higher dose as they expected better
therapeutic results. However, a literature review showed that
there is no linear relation between IL-2 dose and therapeutic
effect (6). Moreover, a negative dose-response effect would be
quite unexpected. 
In both pilot studies, there were no side-effects observed due
to intravesical IL-2 instillations. 
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Table IV. Time (months) between treatment and recurrence after
complete TUR and local IL-2*.
Patient Months between No recurrence during 
number treatment and whole follow-up 
recurrence period (Months)
1 2
2 3
3 2
4 16
5 10
6 1
7 >87
8 3
9 6
10 >86
11 34
12 2
13 17
14 3
15 3
16 14
17 38
18 4
19 79
20 7
21 7
22 14
23 68
24 14
25 2
26 2
*Clinical study performed in Vilnius; preliminary data have been
published (16, 17).
Beside the study in Krakow, seven other studies (11, 18-
25) suggest that IL-2 instillation in the bladder may exert
therapeutic effects. These data are summarized in Table VII.
This table shows that direct contact between bladder
carcinoma and IL-2 (column 2) leads to an impressive
number of complete remissions (CRs) (column 3). In seven
studies (that is all mentioned studies except that of Grasso et
al, (24)) comprising 66 patients, there were 27 CRs (41%)
and 8 partial remissions (PRs) (12%). That is very high, but
similar to the proportion of patients without a recurrence
during the follow-up that we found in Krakow. Although the
number of patients is small, it is clear from the data in Table
VII that contact between IL-2 and tumour cells can induce a
CR. In the study of Grasso et al. (24) no CR was observed in
27 patients, but the percentage of historical recurrences per
year was 95% and this was reduced to 33% in this study.
Taken together, each of these eight studies indicates a clear
therapeutic effect of local IL-2 in direct contact with bladder
carcinoma. Only, the study of IL-2 installation after complete
TUR of bladder carcinoma failed to show therapeutic
efficacy.
We are aware that IL-2 is regarded as a stimulator of an
effective cytotoxic reaction, as well as stimulating T-reg cell
expansion leading to immune suppression (7, 25, 26). These
seemingly contradictory effects of IL-2 may be due to
differences in the doses of IL-2 that are used, the site of IL-2
application (7, 27), or the stage of the immune reaction, such as
stimulation at an early or a late stage in the immune reaction.
We did not observe any example of IL-2-induced stimulation
of tumour growth. 
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Figure 1. Kaplan-Meier curve of the proportion of recurrence-free patients versus time after incomplete and complete TUR. The fraction of patients
that were recurrence-free after local IL-2 and incomplete TUR (line; Krakow, Poland) and complete TUR (stripes; Vilnius, Lithuania). The X-axis
indicates months after treatment with (in)complete TUR and local IL-2; the Y-axis indicates the fraction of patients having recurrence free survival.
Circles are used to indicate censored data. Table V provides statistical analyses. Table VI summarizes differences in the patients populations of both
studies and the predicted effect of several parameters values on the predicted RFS after incomplete versus complete TUR.
Table V. Therapeutic outcome of after incomplete and complete TUR and local IL-2 application.
Incomplete TUR Complete TUR Incomplete/ Therapeutic result 
complete TUR incomplete TURb
30 Months recurrence-free 50% 23% 2.2 Much better
Median recurrence-free survival (months) >20.5 7 >2.9 Much better
Hazard ratio (Kaplan Meier) an.a. n.a. 0.53 Much better
an.a. Not applicable; binterpretation of therapeutic outcome from a patient’s perspective
The Kuhnian paradigm of immunotherapy of cancer is that
an antigen, in this case TAA, induces a local immune reaction
that leads to a cure (7). If a tumour is removed by a complete
TUR, then TAA are not present to induce an immune reaction.
The results described in this paper are exactly what the
immunotherapeutic paradigm predicts.
It is clear that the therapeutic differences described in this
article warrant a new study with the presence/absence of the
marker tumour followed by IL-2 instillation. Currently we are
performing such a randomized trial in the Netherlands
(EudraCT number 2010-020397-42). If the data reported here
are confirmed in this new ongoing trial, then the treatment of
NMIBC with immunotherapy might be improved. 
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